Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong revenue growth and a solid financial position, but also highlights increasing losses and expenses. The Q&A reveals concerns about reimbursement and regulatory challenges, although the company is optimistic about future developments. The absence of clear guidance and specifics on certain issues could cause uncertainty. The combination of these factors suggests a neutral sentiment, as positive developments are balanced by potential risks and uncertainties.
Key Financial Performance
Net Product Revenue (Launch Period May-Dec 2025) $30.9 million, with $17.5 million in Q4. This reflects steady growth driven by consistent adoption among academic centers and community oncologists.
Cost of Sales $2.6 million for Q4 2025 and $4.6 million for the full year. The increase aligns with the rise in net product revenue.
Research and Development (R&D) Expenses $31.7 million for Q4 2025 and $114.6 million for the full year. Driven by ongoing clinical trials (RAMP 301 and VS-7375) and higher costs for drug substance production.
Selling, General, and Administrative (SG&A) Expenses $24.4 million for Q4 2025 and $81.1 million for the full year. Expenses were driven by commercial activities and personnel costs for the CO-PACK launch.
Non-GAAP Adjusted Net Loss $39.8 million ($0.48 per share diluted) for Q4 2025, compared to $29.3 million ($0.60 per share diluted) in Q4 2024. For the full year 2025, the loss was $163.1 million ($2.35 per share diluted), compared to $107.4 million ($3.01 per share diluted) in 2024. The increase reflects higher R&D and SG&A expenses.
Cash, Cash Equivalents, and Investments $205 million as of December 2025, with a pro forma balance of $234.4 million including proceeds from exercised cash warrants. This provides a cash runway into the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
FDA approval of AVMAPKI FAKZYNJA CO-PACK: First treatment specifically for KRAS-mutated recurrent low-grade serous ovarian cancer approved in May 2025. Generated $30.9 million in net product revenue for 2025.
Clinical trials for avutometinib and defactinib: RAMP 301 Phase III trial and RAMP 205 trial in pancreatic cancer completed enrollment ahead of schedule. Promising results in pancreatic cancer with 83% response rate in early data.
VS-7375 development: Advanced to clinical trials with potential best-in-class oral KRAS G12D ON/OFF inhibitor. FDA feedback received for Phase II registration-directed trials.
Market adoption of AVMAPKI FAKZYNJA CO-PACK: Steady growth with nearly 300 prescribers and strong adoption in academic and community centers. Plans for a new promotional campaign in 2026 to drive awareness and adoption.
Expansion into international markets: Received orphan drug designation in Europe for ovarian cancer. Japan-specific RAMP 201J study showed promising results.
Financial performance: $17.5 million in Q4 2025 revenue, $30.9 million for the year. Cash runway extended into 2027 with CO-PACK revenues expected to sustain operations by H2 2026.
Cost management: Disciplined expense management with SG&A expenses expected to remain stable in 2026.
Pipeline prioritization: Focus on high-value opportunities like VS-7375 and discontinuation of avutometinib plus defactinib in lung cancer due to evolving landscape.
Future clinical milestones: Plans to share updates on RAMP 205 and VS-7375 trials in 2026. Phase II registration-directed trials for KRAS G12D cancers being developed.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
NCCN ovarian cancer guidelines update: The updated guidelines did not expand the recommendation for avutometinib plus defactinib to include patients with recurrent LGSOC without a KRAS mutation. This limits the potential market and leaves patients with KRAS wild-type recurrent LGSOC without targeted FDA-approved treatment options.
Clinical trial outcomes and regulatory hurdles: The company is relying on future data from the RAMP 301 Phase III trial to potentially expand indications for avutometinib plus defactinib. Delays or negative outcomes in these trials could hinder regulatory approvals and market expansion.
Resource allocation and financial constraints: The company has limited resources and must prioritize high-value opportunities. This could delay or limit the development of other promising programs.
Market adoption challenges: Despite initial success, the adoption of AVMAPKI FAKZYNJA CO-PACK in first recurrence settings is slow, as many physicians are initially using it in later lines of treatment. Building awareness and comfort among prescribers remains a challenge.
Competition and evolving treatment landscape: The discontinuation of avutometinib plus defactinib in lung cancer highlights challenges in competing within an evolving treatment landscape. This could impact the company's ability to maintain a competitive edge.
Pipeline development risks: The development of VS-7375, a KRAS G12D inhibitor, is in early stages. Any setbacks in clinical trials or regulatory feedback could delay its progress and impact the company's strategic goals.
Economic and payer environment: The company operates in a challenging economic and payer environment, which could impact pricing, reimbursement, and overall financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections: The company expects the LGSOC franchise to be self-sustaining in the second half of 2026, with CO-PACK revenues funding both commercial operations and ongoing clinical trials.
Clinical Trials and Data Updates: The RAMP 301 confirmatory Phase III trial in recurrent LGSOC is expected to report top-line primary analysis in mid-2027. The RAMP 205 trial in first-line metastatic pancreatic cancer will share an update on the expansion cohort in Q2 2026. Preliminary data for the VS-7375 trial will be shared in the first half of 2026, with a more comprehensive update in the second half of the year.
Pipeline Development: The company is advancing the VS-7375 program with Phase II registration-directed trials for KRAS G12D mutated cancers, including pancreatic, lung, and colorectal cancers. The goal is to expedite the execution of the registration path in major KRAS G12D solid tumors.
Commercial Strategy: Plans for 2026 include launching a new promotional campaign to increase awareness and adoption of AVMAPKI FAKZYNJA CO-PACK, expanding educational programs for physicians, and deploying additional field staff to support the commercial launch.
Financial Outlook: The company has extended its cash runway into the first half of 2027, supported by current cash reserves and future revenues from CO-PACK sales.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why were wild-type patients not included in the NCCN update, and is there confidence in continued reimbursement for these patients?
A:The company was disappointed and surprised by the exclusion of wild-type patients in the NCCN update. They suspect it might be related to the imminent Phase III readout. Despite this, the team has been successful in securing reimbursement for wild-type patients and will continue their efforts. They believe the confirmatory study results will drive ultimate adoption.
Q:What is the safety profile of 7375 in the U.S. study, and how is dose selection being approached?
A:The safety profile is very good, with low dose modifications and dropout rates. Dose escalation is being evaluated up to 1,200 mg, with a focus on long-term tolerability and durable antitumor responses. The company is confident in identifying proper doses within a few months.
Q:What is the long-term positioning strategy for 7375 in the RAS space?
A:The strategy includes moving the drug into second and third-line settings for accelerated approval and eventually into frontline studies with standard care. They are also considering novel combinations through investigator-sponsored trials.
Q:Are there plans to reengage with the NCCN in the future with longer-term data?
A:Yes, the company plans to develop more evidence on the molecule's use in both wild-type and mutated cases. They aim to use the RAMP 301 readout to support NCCN reengagement and potential FDA label expansion.
Q:What triggered the FDA feedback to separate the study into disease-specific and registration-directed Phase II trials?
A:The FDA suggested separating protocols for marketing authorization purposes, aligning with their division of solid tumor categories. This administrative change does not impact safety or informed consent.
Q:What are the prescribing dynamics for CO-PACK, and how is financing being approached?
A:CO-PACK has nearly 300 new prescribers, with 75% of top institutions adopting it. Prescriptions are split 60-40 between GynOncs and MedOncs, with more than half from academic centers. Financing is being carefully managed, with a focus on non-dilutive approaches and strategic interest to extend the cash runway beyond 2027.
Q:What insights are there into the safety differences of 7375 between U.S. and China populations?
A:The U.S. population shows better safety, likely due to better bone marrow support and less use of natural products that may cause liver issues. Side effects like nausea and diarrhea are manageable with standard treatments.
Q:What is the impact of the protocol update on clinical development?
A:The update is an administrative change to separate protocols for FDA alignment, with no significant timeline impact or changes to patient enrollment criteria.
Q:Is dose titration being considered for 7375?
A:The company is open to dose titration but currently sees no need to lower doses, as the 900 mg dose is well-tolerated.
Q:What are the next steps for the RAMP 201J trial in Japan?
A:The trial sites have been converted to the confirmatory study, and the company plans to meet with the PMDA to discuss using the bridging study for conditional approval, aiming to file early next year.
Q:What is the payer coverage situation for KRAS wild-type patients in the U.S. launch?
A:KRAS wild-type patients are the third largest group, with good success in securing reimbursement. There has been some tightening for totally off-label cases like brain and lung cancers.
Q:Review of Unclear Management Responses
A:Management avoided providing specific numbers on the payer coverage of KRAS wild-type patients and the exact number of cases covered since launch. They also did not detail the activities planned for reengaging with the NCCN or the specific formulation improvements for 7375.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CO PACK
Cares program
Full
II registration
II trial
Japan
KRAS mutation
LGSOC KRAS
LGSOC franchise
LGSOC support
PACK revenue
Phase II
President Development
RAS cancer
United States
activity cancer
addition
afternoon
agent
analysis
campaign
defactinib combination
escalation
event
exposure
guideline
line cancer
milligram dose
outcome
partner China
pathway
patient LGSOC
period
protocol
response rate
signal
tool
treatment KRAS
tumor
VSTM Transcript
Verastem, Inc. (VSTM) Q1 2026 Earnings Call Transcript
Positive5-7
The earnings call indicates a positive outlook with a 25% revenue increase and reduced net loss, despite increased R&D expenses. The company's strategic plan includes self-sustaining revenue projections and a commercial strategy for 2026, suggesting growth potential. However, the call lacked detailed strategic initiatives and operational updates, and highlighted risks in regulatory and market conditions. Overall, the financial performance and optimistic future plans outweigh the risks, leading to a positive sentiment.
Verastem, Inc. (VSTM) Q4 2025 Earnings Call Transcript
Unknown3-4
The earnings call summary indicates strong revenue growth and a solid financial position, but also highlights increasing losses and expenses. The Q&A reveals concerns about reimbursement and regulatory challenges, although the company is optimistic about future developments. The absence of clear guidance and specifics on certain issues could cause uncertainty. The combination of these factors suggests a neutral sentiment, as positive developments are balanced by potential risks and uncertainties.
Verastem, Inc. (VSTM) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call reflects positive sentiment due to early adoption of the new product, a strong financial runway, and strategic plans for clinical trials and market expansion. Despite some uncertainties in patient data and NCCN feedback, the overall outlook is optimistic with potential for label expansion and interest from partners. The positive adoption and feedback from healthcare providers, combined with a solid cash position, suggest a favorable stock price reaction.
Verastem, Inc. (VSTM) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance, positive product development updates, and effective market strategy, with minimal payer pushback and successful reimbursement strategies. The Q&A section reinforced positive sentiment with management's confidence in launch momentum and successful engagement with the healthcare community. Despite some uncertainties in EU approval timelines, the overall outlook is optimistic, with a focus on expansion and minimal financial concerns.
VSTM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
